Sham-controlled RCT in 60 adults with PPI-responsive GERD: antireflux mucosal ablation was not superior to sham for 12-month clinical success (51.6% vs 37.9%; P=0.29) and caused more pain (27.3% vs 3.3%) and dysphagia (45.5% vs 10.0%).
RCTn = 60
Rodríguez de Santiago et al. Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease